Updated version of this database is available at ThpDB2

Detailed description page of THPdb

This page displays user query in tabular form.

Th1069 details
Primary information
ID1415
ThPP IDTh1069
Therapeutic Peptide/Protein NamePegvisomant
SequenceFPTIPLSRLFDNAMLRAHRLHQLAFDTYQEFEEAYIPKEQKYSFLQNPQT view full sequnce in fasta
Functional ClassificationIIa
Molecular Weight22129
Chemical FormulaC990H1532N262O300S7
Isoelectric Point5.27
Hydrophobicity-0.411
Melting Point (℃)76
Half Life6 days
DescriptionPegvisomant is a highly selective growth hormone (GH) receptor antagonist. It is used to treat acromegaly. Unlike dopamine or somatostatin analogs (which inhibit growth hormone secretion), this drug actually blocks the hepatic (GH-mediated) production of insulin like growth factor (IGF-1), which is the main mediator of growth hormone activity.
Indication/DiseasePegvisomant is a growth hormone receptor antagonist used for the treatment of acromegaly.
PharmacodynamicsSomavert is used for the treatment of acromegaly, which arises from excessive IGF-1 levels. Somavert selectively binds to growth hormone (GH) receptors on cell surfaces, where it blocks the binding of endogenous GH, and thus interferes with GH signal transduction. Inhibition of GH action results in decreased serum concentrations of insulin-like growth factor-I (IGF-I), and IGF binding protein-3 (IGFBP-3). This reduces the symptoms of acromegaly.
Mechanism of ActionSomavert selectively binds to growth hormone (GH) receptors on cell surfaces, where it blocks the binding of endogenous GH. This leads to the normalization of serum IGF-1 levels.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of Distribution7 L
Clearance36 ± 28 mL/h [SC doses ranging from 10 to 20 mg/day]
CategoriesHormone Replacement Agents
Patents NumberUS5849535
Date of Issue26/03/01
Date of Expiry26/03/21
Drug InteractionDihydrocodeine opioids may diminish the therapeutic effect of pegvisomant. It is recommended to monitor therapy
TargetN.A.
Information of corresponding available drug in the market
Brand NameSOMAVERT
CompanyPfizer
Brand DiscriptionSOMAVERT contains pegvisomant, an analog of human growth hormone (GH) that has been structurally altered to act as a GH receptor antagonist.Pegvisomant is a protein of recombinant DNA origin containing 191 amino acid residues to which several polyethylene glycol (PEG) polymers are covalently bound (predominantly 4 to 6 PEG/protein molecule). The molecular weight of the protein of pegvisomant is 21,998 Daltons.
Prescribed forSOMAVERT is indicated for the treatment of acromegaly in patients who have had an inadequate response to surgery or radiation therapy, or for whom these therapies are not appropriate. The goal of treatment is to normalize serum insulin-like growth factor-I (IGF-I) levels.
Chemical NameN.A.
FormulationSOMAVERT is available in single-dose sterile vials containing 10, 15, or 20 mg of pegvisomant protein (approximately 10, 15, and 20 U activity, respectively). Each vial also contains 1.36 mg of glycine, 36.0 mg of mannitol, 1.04 mg of sodium phosphate dibasic anhydrous, and 0.36 mg of sodium phosphate monobasic monohydrate
Physcial AppearanceSOMAVERT for injection is supplied as a Sterile, white lyophilized powder 
Route of AdministrationSubcutaneous Injection
Recommended DosageThe recommended loading dose of SOMAVERT is 40 mg given subcutaneously, under healthcare provider supervision. Increase the dosage by 5 mg increments every 4-6 weeks if IGF-I concentrations are elevated.Decrease the dosage by 5 mg decrements every 4-6 weeks if IGF-I concentrations are below the normal range.
ContraindicationNone.
Side EffectsHypoglycemia associated with GH lowering in patients with Diabetes Mellitus, Liver test elevations, Cross-reactivity with GH assay, Lipohypertrophy, Systemic hypersensitivity, pain, nausea ,diarrhea, dizziness, Sinusitis
Useful Linkhttp://www.rxlist.com/somavert-drug.htm http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=222a28ca-70c3-474c-850e-fae39eaaf40f
PubMed ID20444908, 18778113, 17207591, 16311417, 15134290, 15006735, 14499709, 12200225, 11932320
3-D StructureTh1069 (View) or (Download)
Primary information
ID1416
ThPP IDTh1069
Therapeutic Peptide/Protein NamePegvisomant
SequenceFPTIPLSRLFDNAMLRAHRLHQLAFDTYQEFEEAYIPKEQKYSFLQNPQT view full sequnce in fasta
Functional ClassificationIIa
Molecular Weight22129
Chemical FormulaC990H1532N262O300S7
Isoelectric Point5.27
Hydrophobicity-0.411
Melting Point (℃)76
Half Life6 days
DescriptionPegvisomant is a highly selective growth hormone (GH) receptor antagonist. It is used to treat acromegaly. Unlike dopamine or somatostatin analogs (which inhibit growth hormone secretion), this drug actually blocks the hepatic (GH-mediated) production of insulin like growth factor (IGF-1), which is the main mediator of growth hormone activity.
Indication/DiseasePegvisomant is a growth hormone receptor antagonist used for the treatment of acromegaly.
PharmacodynamicsSomavert is used for the treatment of acromegaly, which arises from excessive IGF-1 levels. Somavert selectively binds to growth hormone (GH) receptors on cell surfaces, where it blocks the binding of endogenous GH, and thus interferes with GH signal transduction. Inhibition of GH action results in decreased serum concentrations of insulin-like growth factor-I (IGF-I), and IGF binding protein-3 (IGFBP-3). This reduces the symptoms of acromegaly.
Mechanism of ActionSomavert selectively binds to growth hormone (GH) receptors on cell surfaces, where it blocks the binding of endogenous GH. This leads to the normalization of serum IGF-1 levels.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of Distribution8 L
Clearance37 ± 28 mL/h [SC doses ranging from 10 to 20 mg/day]
CategoriesHormone Replacement Agents
Patents NumberUS5350836
Date of Issue28/09/98
Date of Expiry28/09/15
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsN.A.
Useful LinkN.A.
PubMed ID20444908, 18778113, 17207591, 16311417, 15134290, 15006735, 14499709, 12200225, 11932320
3-D StructureTh1069 (View) or (Download)
Primary information
ID1417
ThPP IDTh1069
Therapeutic Peptide/Protein NamePegvisomant
SequenceFPTIPLSRLFDNAMLRAHRLHQLAFDTYQEFEEAYIPKEQKYSFLQNPQT view full sequnce in fasta
Functional ClassificationIIa
Molecular Weight22129
Chemical FormulaC990H1532N262O300S7
Isoelectric Point5.27
Hydrophobicity-0.411
Melting Point (℃)76
Half Life6 days
DescriptionPegvisomant is a highly selective growth hormone (GH) receptor antagonist. It is used to treat acromegaly. Unlike dopamine or somatostatin analogs (which inhibit growth hormone secretion), this drug actually blocks the hepatic (GH-mediated) production of insulin like growth factor (IGF-1), which is the main mediator of growth hormone activity.
Indication/DiseasePegvisomant is a growth hormone receptor antagonist used for the treatment of acromegaly.
PharmacodynamicsSomavert is used for the treatment of acromegaly, which arises from excessive IGF-1 levels. Somavert selectively binds to growth hormone (GH) receptors on cell surfaces, where it blocks the binding of endogenous GH, and thus interferes with GH signal transduction. Inhibition of GH action results in decreased serum concentrations of insulin-like growth factor-I (IGF-I), and IGF binding protein-3 (IGFBP-3). This reduces the symptoms of acromegaly.
Mechanism of ActionSomavert selectively binds to growth hormone (GH) receptors on cell surfaces, where it blocks the binding of endogenous GH. This leads to the normalization of serum IGF-1 levels.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of Distribution9 L
Clearance38 ± 28 mL/h [SC doses ranging from 10 to 20 mg/day]
CategoriesHormone Replacement Agents
Patents NumberCA2230492
Date of Issue27/05/13
Date of Expiry21/09/20
Drug InteractionN.A.
TargetB-lymphocyte antigen CD20,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immunoglobulin gamma Fc region receptor III-A,High affinity immunoglobulin gamma Fc receptor I,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsN.A.
Useful LinkN.A.
PubMed ID20444908, 18778113, 17207591, 16311417, 15134290, 15006735, 14499709, 12200225, 11932320
3-D StructureTh1069 (View) or (Download)
Primary information
ID1418
ThPP IDTh1069
Therapeutic Peptide/Protein NamePegvisomant
SequenceFPTIPLSRLFDNAMLRAHRLHQLAFDTYQEFEEAYIPKEQKYSFLQNPQT view full sequnce in fasta
Functional ClassificationIIa
Molecular Weight22129
Chemical FormulaC990H1532N262O300S7
Isoelectric Point5.27
Hydrophobicity-0.411
Melting Point (℃)76
Half Life6 days
DescriptionPegvisomant is a highly selective growth hormone (GH) receptor antagonist. It is used to treat acromegaly. Unlike dopamine or somatostatin analogs (which inhibit growth hormone secretion), this drug actually blocks the hepatic (GH-mediated) production of insulin like growth factor (IGF-1), which is the main mediator of growth hormone activity.
Indication/DiseasePegvisomant is a growth hormone receptor antagonist used for the treatment of acromegaly.
PharmacodynamicsSomavert is used for the treatment of acromegaly, which arises from excessive IGF-1 levels. Somavert selectively binds to growth hormone (GH) receptors on cell surfaces, where it blocks the binding of endogenous GH, and thus interferes with GH signal transduction. Inhibition of GH action results in decreased serum concentrations of insulin-like growth factor-I (IGF-I), and IGF binding protein-3 (IGFBP-3). This reduces the symptoms of acromegaly.
Mechanism of ActionSomavert selectively binds to growth hormone (GH) receptors on cell surfaces, where it blocks the binding of endogenous GH. This leads to the normalization of serum IGF-1 levels.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of Distribution10 L
Clearance39 ± 28 mL/h [SC doses ranging from 10 to 20 mg/day]
CategoriesHormone Replacement Agents
Patents NumberCA2102129
Date of Issue02/04/07
Date of Expiry02/05/16
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsN.A.
Useful LinkN.A.
PubMed ID20444908, 18778113, 17207591, 16311417, 15134290, 15006735, 14499709, 12200225, 11932320
3-D StructureTh1069 (View) or (Download)